Journal ArticleDOI
Developments of CRBN-based PROTACs as potential therapeutic agents
TLDR
A comprehensive review on the latest research progress in CRBN-based PROTACs can be found in this paper, where the degradants are presented in alphabetical order by target.About:
This article is published in European Journal of Medicinal Chemistry.The article was published on 2021-08-10. It has received 48 citations till now. The article focuses on the topics: Protein degradation.read more
Citations
More filters
Journal ArticleDOI
Targeted protein degradation: mechanisms, strategies and application
TL;DR: In this article , the authors summarize recent advances of major targeted protein degradation (TPD) technologies, discuss their potential applications, and hope to provide a prime for both biologists and chemists who are interested in this vibrant field.
Journal ArticleDOI
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Corinna Eich,Jinlin Yang +1 more
TL;DR: Proteolysis targeting chimeras (PROTACs) are a novel drug discovery paradigm that has been widely used as biological tools and medicinal molecules with the potential of clinical application value as discussed by the authors .
Journal ArticleDOI
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
TL;DR: Proteolysis targeting chimeras (PROTACs) are a novel drug discovery paradigm that has been widely used as biological tools and medicinal molecules with the potential of clinical application value.
Journal ArticleDOI
PROTACs for BRDs proteins in cancer therapy: a review
TL;DR: A comprehensive overview of the development of PROTACs for BRDs proteins regulation in cancer is presented, and the chances and challenges associated with this area are also highlighted.
Journal ArticleDOI
Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
Chao Wang,Yujing Zhang,Lingyu Shi,Shanbo Yang,Jing Chang,Yingjie Zhong,Qian Li,Dongming Xing +7 more
TL;DR: This review of IAP-based PROTACs will present the most relevant advances in the field of SNIPERs and provide the perspective on the opportunities and challenges for SNIPERS to become therapeutic agents.
References
More filters
Journal ArticleDOI
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
TL;DR: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
Journal ArticleDOI
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E. Hynes,Heidi Lane +1 more
TL;DR: This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.
Journal ArticleDOI
Epidermal growth factor receptor mutations in lung cancer
TL;DR: 'oncogenic shock' is described as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors, essential to the successful use of targeted therapies in common epithelial cancers.
Journal ArticleDOI
The Polycomb complex PRC2 and its mark in life
Raphaël Margueron,Danny Reinberg +1 more
TL;DR: This work has uncovered a role for non-coding RNA in the recruitment of PRC2 to target genes, and expanded the perspectives on its function and regulation.
Journal ArticleDOI
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
TL;DR: The biochemical, structural and genetic studies that have clarified how the interplay between members of the BCL-2 family on mitochondria sets the apoptotic threshold are discussed, illuminating the physiological control of apoptosis, the pathological consequences of its dysregulation and the promising search for novel cancer therapies that target the BCA2 protein family.